menu
    • menu
    [{"orgOrder":0,"company":"Teva Pharma (Thailand)","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"THAILAND","productType":"Carbohydrate","year":"2024","type":"Acquisition","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Teva Pharma (Thailand)","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharma (Thailand) \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharma (Thailand) \/ Lotus Pharmaceutical Industries"}]

    Find Clinical Drug Pipeline Developments & Deals by Teva Pharma (Thailand)

    Menu

    Teva Pharma (Thailand)

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Teva Pharma (Thailand)

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Teva Pharma (Thailand)

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Lotus Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Taiwan's Lotus Pharma acquires Teva Pharma Thailand, expanding footprint in Southeast Asia

                            Details : Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including NATEAR (hydroxypropyl methylcellulose) used as artificial tears to prevent conjunctival and corneal damage.

                            Product Name : Natear

                            Product Type : Carbohydrate

                            Upfront Cash : Undisclosed

                            June 06, 2024

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Lotus Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth